Cocrystal Pharma, Inc. Files 2023 Annual Report on Form 10-K

TL;DR

<b>Cocrystal Pharma, Inc. has filed its 2023 annual report (10-K), detailing its financial status and corporate history.</b>

AI Summary

Cocrystal Pharma, Inc. (COCP) filed a Annual Report (10-K) with the SEC on March 28, 2024. Cocrystal Pharma, Inc. filed its 2023 Form 10-K on March 28, 2024. The company's fiscal year ends on December 31st. Cocrystal Pharma, Inc. was formerly known as BIOZONE PHARMACEUTICALS, INC. and International Surf Resorts, Inc. The company's business address is located at 19805 N. CREEK PARKWAY, BOTHELL, WA 98011. The filing includes data related to common stock, additional paid-in capital, and retained earnings for fiscal years 2021, 2022, and 2023.

Why It Matters

For investors and stakeholders tracking Cocrystal Pharma, Inc., this filing contains several important signals. This 10-K filing provides a comprehensive overview of Cocrystal Pharma's financial performance and position for the fiscal year ended December 31, 2023, which is crucial for investors to assess the company's health and future prospects. Understanding the company's historical name changes and corporate structure, as detailed in the filing, is important for tracking its evolution and potential strategic shifts.

Risk Assessment

Risk Level: low — Cocrystal Pharma, Inc. shows low risk based on this filing. The filing is a standard 10-K annual report, which typically contains historical financial data and risk factors, but does not indicate any immediate or significant new risks or positive developments.

Analyst Insight

Review the detailed financial statements and risk factors within the 10-K to understand Cocrystal Pharma's current financial health and potential challenges.

Key Numbers

• 2023-12-31 — Fiscal Year End (Reported period)
• 2024-03-28 — Filing Date (Date of submission)
• 10-K — Form Type (Type of SEC filing)
• 0001412486 — Central Index Key (Company identifier)

Key Players & Entities

• Cocrystal Pharma, Inc. (company) — Filer name
• BIOZONE PHARMACEUTICALS, INC. (company) — Former company name
• International Surf Resorts, Inc. (company) — Former company name
• 19805 N. CREEK PARKWAY (location) — Business address street
• BOTHELL (location) — Business address city
• WA (location) — Business address state
• 98011 (location) — Business address zip
• 20231231 (date) — Fiscal year end

FAQ

Industry Context

Cocrystal Pharma, Inc. operates in the Pharmaceutical Preparations industry, focusing on the development and commercialization of antiviral therapeutics.

Regulatory Implications

As a publicly traded company, Cocrystal Pharma, Inc. is subject to the regulations of the Securities and Exchange Commission (SEC), requiring regular filings such as the 10-K.

What Investors Should Do

1. Analyze the financial statements (balance sheets, income statements, cash flow statements) for the fiscal year ended December 31, 2023.
2. Review the 'Risk Factors' section of the 10-K to identify potential challenges and uncertainties facing the company.
3. Examine any disclosures related to executive compensation, material agreements, or legal proceedings.

Key Dates

• 2023-12-31: Fiscal Year End — End of the reporting period for the 10-K.
• 2024-03-28: Filing Date — Date Cocrystal Pharma, Inc. submitted its 10-K filing.

Year-Over-Year Comparison

This filing is the 2023 annual report (10-K), providing a comprehensive update compared to previous filings which would include quarterly reports (10-Q) and potentially other material event filings.

Key Financial Figures

• $0.001 — registered Common Stock, par value $0.001 per share COCP The Nasdaq Stock Mar
• $10.4 billion — luenza is responsible for approximately $10.4 billion in direct medical costs in the U.S. ann
• $10.6 billion — e annual burden to the United States at $10.6 billion. Noroviruses are responsible for up to

Filing Documents

• form10-k.htm (10-K) — 1374KB
• ex14-1.htm (EX-14.1) — 80KB
• ex19-1.htm (EX-19.1) — 124KB
• ex23-1.htm (EX-23.1) — 5KB
• ex31-1.htm (EX-31.1) — 13KB
• ex31-2.htm (EX-31.2) — 12KB
• ex31-3.htm (EX-31.3) — 12KB
• ex32-1.htm (EX-32.1) — 13KB
• ex97.htm (EX-97.1) — 43KB
• 0001493152-24-011613.txt (&nbsp;) — 6220KB
• cocp-20231231.xsd (EX-101.SCH) — 46KB
• cocp-20231231_cal.xml (EX-101.CAL) — 62KB
• cocp-20231231_def.xml (EX-101.DEF) — 170KB
• cocp-20231231_lab.xml (EX-101.LAB) — 400KB
• cocp-20231231_pre.xml (EX-101.PRE) — 318KB
• form10-k_htm.xml (XML) — 753KB

Selected Financial Data

Selected Financial Data. 42 Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations. 42 Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk. 46 Item 8.

Financial Statements

Financial Statements. 46 Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure. 47 Item 9A.

Controls and Procedures

Controls and Procedures. 47 Item 9B. Other Information. 47 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections. 47 Part III. 47 Item 10. Directors, Executive Officers and Corporate Governance. 47 Item 11.

Executive Compensation

Executive Compensation. 47 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters. 47 Item 13. Certain Relationships and Related Transactions, and Director Independence. 47 Item 14. Principal Accounting Fees and Services. 47 Part IV. 48 Item 15. Exhibits, Financial Statement Schedules. 48 Item 16. Form 10-K Summary 49

SIGNATURES

SIGNATURES 50 2 PART I Item 1. Business. Overview Cocrystal Pharma, Inc. (the "Company" or "Cocrystal") is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics as treatments for serious and/or chronic viral diseases. We employ unique structure-based technologies and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs. These technologies are designed to efficiently deliver small molecule therapeutics that are safe, effective, and convenient to administer. We have identified promising discovery, preclinical and clinical stage antiviral compounds for unmet medical needs caused by RNA viruses including influenza virus, coronaviruses (including SARS-CoV-2 & MERS-CoV), norovirus, respiratory virus infections and hepatitis C virus ("HCV") infections. The Company operates as one business entity. Cocrystal Technology We are developing small molecule antiviral therapeutics that inhibit the essential viral replication function of RNA viruses causing acute and chronic viral diseases. Our goals include treating and preventing influenza virus, coronavirus, and norovirus infections by discovering and developing drug candidates targeting required steps in the viral replication process. Additionally, one of our goals is to decrease the duration of HCV therapy. To discover and design these virus replication inhibitors, we use a proprietary platform comprising computational chemistry, medicinal chemistry, X-ray crystallography and our extensive know-how. We determine the structures of cocrystals containing the inhibitors bound to the viral enzyme or protein to guide our structure-based drug design. We also use advanced computational methods to screen and design product candidates using proprietary cocrystal structural information. In designing the candidates, we seek to anticipate and avert potential viral mutations leading to resistance. By designing and selecting drug candidates that interrupt t

View Full Filing

View this 10-K filing on SEC EDGAR